

DOCKET NO: 2001-013

1646
RECEIVED #4

JUL 25 2001

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of :
S. Muller et al. :
Serial No: 09/759,112 : Art Unit: 1646
Filed: January 11, 2001 : Examiner: Unassigned
For: NUCLEOTIDE SEQUENCES ENCOD-:
ING VARIABLE REGIONS OF HEAVY :
AND LIGHT CHAINS OF MONOCLONAL :
ANTIBODY 1F7, AN ANTI-IDIOTYPIC :
ANTIBODY REACTIVE WITH ANTI-HIV :
ANTIBODIES :

TRANSMITTAL OF COMPUTER-READABLE FORM

Box Sequence
Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

A computer readable form of the written Sequence Listing filed in the above-referenced patent application is submitted herewith on a computer disk. The Sequence Listing is stored as a Patent-In document designated "1F7.prj" and as an ASCII text file designated "1F7.ST25.txt".


A copy of the Notice to Comply accompanies.

STATEMENT UNDER 37 CFR 1.821(e)-(g)

The undersigned representative hereby states that the content of the Sequence Listing information recorded in computer


readable form as submitted herewith is identical to the written
Sequence Listing filed in the above-referenced patent
application and contains no new matter.


Respectfully submitted,


James H. Meadows, Ph.D.
Attorney for Applicants
Reg. No. 33,965

Correspondence Address

5355 Mira Sorrento Pl.-Ste. 100
San Diego, CA 92121
Tel: 619-501-7720
Fax: 503-217-9394
Date: July 19, 2001

I, James H. Meadows, hereby certify that this correspondence is being deposited with the U.S. Postal Service with
sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington,
D.C. 20231 on July 19, 2001 Signature 

Page 1 of 2
RECEIVED

JUL 25 2001

TECH CENTER 1600/2900

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

| APPLICATION NUMBER | FILING/RECEIPT DATE | FIRST NAMED APPLICANT | ATTORNEY DOCKET NUMBER |
|--------------------|---------------------|-----------------------|------------------------|
| 09/759,112 | 01/11/2001 | Sybillie Muller | 200-013 |

23511
MEDICUS ASSOCIATES AND JAMES H MEADOWS
5355 MIRA SORRENTO PL., SUITE 100
SAN DIEGO, CA 92121**CONFIRMATION NO. 1831****FORMALITIES LETTER**

OC000000006109228

Date Mailed: 05/23/2001

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE
DISCLOSURES**


Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application does not contain a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). Applicant must provide such statement. If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

*A copy of this notice **MUST** be returned with the reply.*


Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE